Filing Flows › Mangoceuticals (MGRX) › Q1 2026 › vs Q4 2025
Mangoceuticals (MGRX) Q1 2026 vs Q4 2025 (quarter over quarter)
Mangoceuticals's revenue fell $26K (-28%) from $94K in Q4 2025 to $68K in Q1 2026.
Mangoceuticals, Q1 2026: revenue $68K (-38% year over year), net loss $3.4M, operating cash flow −$1.3M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $68K | $94K | −$26K | -28% |
| Net loss | $3.4M | $2.8M | $634K | +23% |
| Costs & expenses | $3.5M | $2.9M | $607K | +21% |
| Operating costs | $3.2M | $462K | $2.7M | +591% |
| Interest & other, net | $277K | $2.4M | −$2.1M | -88% |
| Cost of revenue | $39K | $47K | −$8K | -17% |
| Operating cash sources | $3.4M | $2.8M | $634K | +23% |
| Depreciation & amortization | $277K | $568K | −$291K | -51% |
| Share-based compensation | $1.1M | $0 | $1.1M | — |
| Working capital & other | $725K | $1.1M | −$399K | -36% |
| Cash used in operations | $1.3M | $1.1M | $234K | +22% |
| Net loss absorbed | $3.4M | $2.8M | $634K | +23% |
Questions
How much did Mangoceuticals's revenue grow quarter over quarter in Q1 2026?
Mangoceuticals's revenue fell $26K (-28%) from $94K in Q4 2025 to $68K in Q1 2026.